Mechanisms underlying tendon pathology in a murine model of menopause - tendon and ligament injuries are common in active and aging populations
Active Project Grant Awarded Last action
- Award ID
- R01AG094740
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $680,011
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 6% complete
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
About this award
The National Institute on Aging, part of the Department of Health and Human Services, awarded The General Hospital Corporation (Massachusetts General Hospital) $680,011 on August 1, 2026, under the Aging Research program (CFDA 93.866, Project Grant R01AG094740).
The award funds research into the molecular mechanisms underlying tendon pathology in a murine model of menopause. The project investigates why postmenopausal women experience accelerated tendon injury and disease compared with similarly aged men, with emphasis on how aging and estrogen deficiency interact to compromise tendon structure and function. The research employs a chemically-induced model that recapitulates progressive menopause transition in middle-aged mice to test variables of age and hormone replacement, addressing a gap in human-relevant experimental models where most prior ovariectomized-mouse studies fail to use aged animals or capture the role of aging and reproductive senescence on tendon phenotypes.
Work is performed at Massachusetts General Hospital's Research Management Division in Boston, Massachusetts. The performance period runs from August 1, 2026, through July 31, 2031.
Description
Because of their slow and limited healing, these injuries present clinical challenges and result in pain and limited mobility for patients. Aging also causes increased tendon calcification and accumulation of advanced glycation end products, which negatively impact tendon health. Notably, postmenopausal women have an accelerated incidence of tendon injury and disease compared with similarly aged males. Menopause is characterized by the loss of ovarian follicles and the depletion of their associated SEX hormones, estrogen and progesterone. Clinical studies indicate that estrogen replacement therapy can mitigate tendon pathologies in postmenopausal women, as evidenced by decreased tendon stiffness and fibril diameters when compared to similarly aged women not receiving therapy. These clinical findings suggest that aging and the loss of SEX hormones, and estrogen in particular, during menopause may contribute to tendon pathology. However, we understand very little of the molecular mechanisms that underly these pathological changes in the tendon, and particularly how age and estrogen deficiency may interact to compromise tendon structure and function. The lack of human-relevant models likely contributes to this GAP in our understanding. While most rodents have an estrous cycle, many retain estrogen levels even into older ages. Ovariectomized (OVX) mice have been used to simulate ovarian dysfunction, yet the OVX studies rarely use aged animals, which do not capture the potential role of aging and reproductive senescence on tendon phenotypes. OVX is also limited by abrupt cessation of ovarian hormone production, which does not mimic human trajectories. This application employs a chemically-induced model that recapitulates a progressive menopause transition in middle aged mice. We propose to formally test the variables of age, reproductive status, and estrogen signaling specifically, on tendon health. Next, we will define the molecular and cellular changes that occur in the tendon during the menopause transition using transcriptomic and epigenetic analysis. We will investigate the direct role of estrogen receptor Α (ERΑ), which is highly expressed in tendon cells, in regulating tendon cell behavior. Finally, we will leverage a network medicine computational framework as an unbiased means to identify and test new pathways with therapeutic potential to improve tendon health in menopause. Altogether, this application seeks to disentangle the role of age and SEX hormones on tendon pathology and to define mechanisms underlying how menopause influences tendon properties, which we anticipate will have important and lasting impacts on women's health.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Spaulding Rehabilitation Hospital Corporation | $196,248 |
Quick answers
Who received award R01AG094740?
R01AG094740 was awarded to The General Hospital Corporation by National Institute on Aging (National Institutes of Health) on August 1, 2026.
How much is award R01AG094740 worth?
$680,011 has been obligated on R01AG094740.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award